EyeGate Pharmaceuticals, a clinical stage company focused on developing products for treating disorders of the eye, today announced the acquisition of Panoptes Pharma, a privately-held clinical stage biotech company focused on developing a novel proprietary small molecule for the treatment of severe eye diseases with a high unmet medical need....
Price consolidating atop the 200 SMA, and recently the 50 SMA. MACD bull cross, and RSI finding strong support on top of the 50 EMA of the RSI convey upside momentum bias (I find the 50 EMA on the 14 RSI to be very informative, I recommend you try it for yourself). I am looking for price to stay supported by 5 day SMA and I will look to buy the wedge breakout to...
Chart is starting to flip bullish on support at LTF's. Will be buying my way down and expecting this gap to close. A little more risk than I normally like to try (8-10%) but 70% run up looking nice and we're seeing lots of tech/bio stock boom lately.
Check my page for a handful of other 50+ % runups Ive charted in the past month. It's gonna be a good month lets get it
Even with the fear of biotech companies flying high when they have successful trials, I like the short today. This is a preliminary study that provided very positive news, however the long term price deterioration of the stock points to a pullback and setbacks. This is speculative, thus good luck trading! Great open if you were long!
EYEG had news today so this helped the stock gain visibilty and momentum finance.yahoo.com
RISK / REWARD swing idea and gap play
RSI is at 53 (not oversold) but is in the area of accumulation.
MACD is moving in positive area
Gap Zone hasn't been filled completely
Relative strength index (RSI-14) for Eyegate Pharmaceuticals, Inc. (EYEG) is at 35.36.
Stock price escalated 6.42% to finalize at $0.58 throughout previous buying and selling session.
EYEG is trading -79.65% downward from the 52-week high mark and 17.24% above from the fifty two-week low mark.
EyeGate Pharmaceuticals Inc. (EYEG) had the misfortune of entering into a worldwide licensing agreement with Valeant Pharmaceuticals International Inc. (VRX) in July 2015, just before scandal rocked the blue chip drug manufacturer. It hit an all-time high at $35 after the news and then plummeted, dropping back into single digits in August. The stock posted lower...